ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
129.922,38
0,69%
S&P 500
6.021,63
0,57%
US Dollar vs BRL
5,8125
0,02%
Bitcoin
92.591,42
0,67%
Brent Oil
72,235
-0,30%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Ultragenyx Pharmaceutical Inc (RARE)

  7. Ultragenyx Pharmaceutical Inc (RARE) Notícias

RARE

Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RARE
DataHoraFonteTítuloCódigoCompanhia
26/11/202418:30GlobeNewswire Inc.Ultragenyx to Participate in Investor Conferences in DecemberNASDAQ:RAREUltragenyx Pharmaceutical Inc
20/11/202418:30GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
12/11/202408:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
09/11/202412:30GlobeNewswire Inc.Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science SummitNASDAQ:RAREUltragenyx Pharmaceutical Inc
05/11/202418:01GlobeNewswire Inc.Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
29/10/202417:05GlobeNewswire Inc.Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
11/10/202417:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/10/202409:00GlobeNewswire Inc.Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis ImperfectaNASDAQ:RAREUltragenyx Pharmaceutical Inc
03/10/202417:30GlobeNewswire Inc.Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
26/09/202409:00GlobeNewswire Inc.Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual MeetingNASDAQ:RAREUltragenyx Pharmaceutical Inc
29/08/202417:30GlobeNewswire Inc.Ultragenyx to Participate in Investor Conferences in SeptemberNASDAQ:RAREUltragenyx Pharmaceutical Inc
23/08/202408:00Business WireTactical Resources, a Growing North American Rare Earth Elements Company, to List on NASDAQNASDAQ:RAREUltragenyx Pharmaceutical Inc
01/08/202417:05GlobeNewswire Inc.Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
25/07/202417:05GlobeNewswire Inc.Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
24/07/202409:00GlobeNewswire Inc.Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research SymposiumNASDAQ:RAREUltragenyx Pharmaceutical Inc
17/07/202417:05GlobeNewswire Inc.Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome ProgramNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/07/202417:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAREUltragenyx Pharmaceutical Inc
14/06/202418:11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RAREUltragenyx Pharmaceutical Inc
13/06/202421:49GlobeNewswire Inc.Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/06/202418:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/06/202417:05GlobeNewswire Inc.Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:RAREUltragenyx Pharmaceutical Inc
12/06/202417:00GlobeNewswire Inc.Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)NASDAQ:RAREUltragenyx Pharmaceutical Inc
11/06/202418:47GlobeNewswire Inc.Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)NASDAQ:RAREUltragenyx Pharmaceutical Inc
04/06/202417:05GlobeNewswire Inc.Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:RAREUltragenyx Pharmaceutical Inc
30/05/202417:00GlobeNewswire Inc.Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)NASDAQ:RAREUltragenyx Pharmaceutical Inc
07/05/202417:30GlobeNewswire Inc.Ultragenyx to Participate at Bank of America’s 2024 Healthcare ConferenceNASDAQ:RAREUltragenyx Pharmaceutical Inc
02/05/202417:00GlobeNewswire Inc.Ultragenyx Reports First Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
30/04/202417:00GlobeNewswire Inc.Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
30/04/202409:00GlobeNewswire Inc.Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)NASDAQ:RAREUltragenyx Pharmaceutical Inc
25/04/202417:30GlobeNewswire Inc.Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RARE

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
ATOM3
ATOMPAR ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Economize até 60%* para TRADER PLUS

1 ano 40%, 2 anos 50% e *3 anos 60%

*Ao longo de 3 anos $ 1475.65 apenas $ 590.25